CureVac
Germany - TübingenBiotechnology
Focus: CureVac is a German mRNA therapeutic company headquartered in Tübingen, focused on developing mRNA-based vaccines and immunotherapies across infectious diseases and oncology. As a publicly listed biotech, it operates at the frontier of mRNA platform technology with a diversified pipeline spanning COVID-19, influenza, rabies, and multiple cancer indications.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About CureVac
AI assessmentNot HiringNo open roles listed right now. Follow CureVac to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from CureVac's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CV8102
RabiesClinical Trials (1)
NCT02238756Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults
Phase 1Help build intelligence for CureVac
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.